A PHASE 2, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, DOSE-RANGING, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF CK-2127107 IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS)

UT Health San Antonio

The UT Health San Antonio, with missions of teaching, research and healing, is one of the country’s leading health sciences universities.

Principal Investigator(s)

Jackson, Carlayne E

Collaborating Institutions

UTDALLAS UTSW

Funded by

CYTOKINETICS, INC

Research Start Date

05/01/2018

Status

Active

Collaborative Project

Clinical Care

Drug Discovery

Neuroscience

Bioscience Research Panel